A sulfonium-stapled peptide nano-vaccine achieved 100% tumor prevention for 11 months and eliminated established colon tumors in 40% of mice by dramatically improving neoantigen delivery and T cell activation.
100% prevention, 11 monthsStapled peptide nano-vaccine prevented all tumors for nearly a year with long-term immune memory and no recurrence
What the researchers found
100% tumor prevention for 11 months without recurrence in the prevention model; 40% complete tumor elimination in established MC-38 colon tumors; potent CTL infiltration into tumor microenvironment; efficient antigen/adjuvant co-delivery to draining lymph nodes.
Why it matters
Neoantigen vaccines could potentially cure cancer by training each patient's immune system against their specific tumor. The stapled peptide approach solves the critical delivery problem that has held back neoantigen vaccines in clinical trials.
The numbers in context
Nano-vaccine stimulated strong tumor-specific T cell responses through enhanced antigen uptake and cross-presentation pathways.
How the study worked
Developed sulfonium-stapled peptide-nucleic acid conjugate self-assembling nanoparticles. Tested in prophylactic (tumor prevention) and therapeutic (established tumor) models using MC-38 colon cancer. Assessed lymph node delivery, antigen presentation, TLR signaling, T cell responses, and systemic toxicity.
Who was studied
Mouse cancer models treated with stapled peptide neoantigen nano-vaccines
What this study cannot tell us
Mouse study — human immune responses are more complex. The MC-38 tumor model is moderately immunogenic, which may favor vaccine approaches. Manufacturing personalized stapled peptide neoparticles for each patient is complex. Only single neoantigen tested in therapeutic model — multi-neoantigen approaches may be needed.
How to read the evidence
Moderate evidence: published in Advanced Science with impressive preclinical results in both prevention and treatment models, but no human data yet.
When this study was published
Published in 2024 in Advanced Science. Among the most promising preclinical cancer vaccine results reported.
The bigger picture
Published in Advanced Science, this study addresses the biggest limitation of personalized cancer vaccines — getting neoantigen peptides into immune cells efficiently. By using stapled peptides that self-assemble with adjuvants, the vaccine achieves the antigen presentation and T cell activation that natural peptide antigens cannot. The 100% prevention and 40% cure rates are among the best reported for any neoantigen vaccine in preclinical models.
Questions still open
- Can this platform be manufactured at scale for personalized patient treatment?
- Would multi-neoantigen stapled peptide vaccines improve the 40% cure rate in established tumors?
- How will this approach perform against less immunogenic or immune-cold tumors?
Common questions
What is a stapled peptide vaccine?
Could this approach cure cancer in humans?
Read the original research
Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.
Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(24), e2307754
Citation
Zhang, Yaping; Jiang, Leying; Huang, Siyong; Lian, Chenshan; Liang, Huiting; Xing, Yun; Liu, Jianbo; Tian, Xiaojing; Liu, Zhihong; Wang, Rui; An, Yuhao; Lu, Fei; Pan, Youdong; Han, Wei; Li, Zigang; Yin, Feng. (2024). Sulfonium-Stapled Peptides-Based Neoantigen Delivery System for Personalized Tumor Immunotherapy and Prevention.. Advanced science (Weinheim, Baden-Wurttemberg, Germany), 11(24), e2307754. https://doi.org/10.1002/advs.202307754